Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Merck
McKinsey
Queensland Health
Fish and Richardson
Medtronic
Fuji
Chinese Patent Office
Boehringer Ingelheim
Baxter

Generated: August 21, 2017

DrugPatentWatch Database Preview

Abbvie Inc Company Profile

« Back to Dashboard

What is the competitive landscape for ABBVIE INC, and what generic alternatives to ABBVIE INC drugs are available?

ABBVIE INC has six approved drugs.

There are twenty-eight US patents protecting ABBVIE INC drugs.

There are five hundred and ninety-seven patent family members on ABBVIE INC drugs in fifty-one countries.

Summary for Applicant: Abbvie Inc

Patents:28
Tradenames:6
Ingredients:6
NDAs:6
Drug Master File Entries: (click here to view)17
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc
DUOPA
carbidopa; levodopa
SUSPENSION;ENTERAL203952-001Jan 9, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Abbvie Inc
TECHNIVIE
ombitasvir; paritaprevir; ritonavir
TABLET;ORAL207931-001Jul 24, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Abbvie Inc
VIEKIRA XR
dasabuvir sodium; ombitasvir; paritaprevir; ritonavir
TABLET, EXTENDED RELEASE;ORAL208624-001Jul 22, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Abbvie Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014► Subscribe► Subscribe
Abbvie Inc
TECHNIVIE
ombitasvir; paritaprevir; ritonavir
TABLET;ORAL207931-001Jul 24, 2015► Subscribe► Subscribe
Abbvie Inc
TECHNIVIE
ombitasvir; paritaprevir; ritonavir
TABLET;ORAL207931-001Jul 24, 2015► Subscribe► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ABBVIE INC drugs

Drugname Dosage Strength Tradename Submissiondate
ritonavir
Capsules100 mg
NORVIR
10/31/2012
ritonavir
Tablets100 mg
NORVIR
12/21/2010

Non-Orange Book Patents for Abbvie Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,034,875Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases► Subscribe
8,691,878Solid pharmaceutical dosage form► Subscribe
8,309,613Solid pharmaceutical dosage form► Subscribe
8,333,990Solid pharmaceutical dosage form► Subscribe
8,809,265Methods for treating HCV► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Abbvie Inc Drugs

Country Document Number Estimated Expiration
Israel225010► Subscribe
Spain2459390► Subscribe
San MarinoT201500225► Subscribe
Portugal2295052► Subscribe
China103826627► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Abbvie Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015013Lithuania► SubscribePRODUCT NAME: DASABUVIRUM; REGISTRATION NO/DATE: EU/1/14/983 20150115
2203431/01Switzerland► SubscribePRODUCT NAME: DASABUVIR; REGISTRATION NO/DATE: SWISSMEDIC 65302 25.11.2014
7 50010-2015Slovakia► SubscribePRODUCT NAME: OMBITASVIR; REGISTRATION NO/DATE: EU/1/14/982/001 20150119
2015011,C2340029Lithuania► SubscribePRODUCT NAME: PARITAPREVIRAS; REGISTRATION NO/DATE: EU/1/14.982 20150115
2015000039Germany► SubscribePRODUCT NAME: OMBITASVIR; REGISTRATION NO/DATE: EU/1/14/982 20150115
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Baxter
Argus Health
McKinsey
Citi
Harvard Business School
Federal Trade Commission
AstraZeneca
Queensland Health
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot